Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

AGP ups price target for Heska to $163.50 from $116.50

Alliance Global Partners raised its price target for Heska (NASDAQ:HSKA) to $163.50 from $116.50 after hosting an investor webcast with the company’s CEO. The stock closed at $116.41 on Nov. 3. Analyst Ben Haynor writes...

November 4, 2020

Markets

SVB Leerink starts Spruce Biosciences at OP; PT $35

SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...

November 3, 2020

Markets

HCW ups STRATA Skin Sciences to buy; PT $3

H.C. Wainwright upgraded STRATA Skin Sciences (NASDAQ:SSKN) to “buy” from “neutral” with a price target of $3. The stock closed at $1.24 on Nov. 2. STRATA is a medical technology company developing and marketing...

November 3, 2020

Markets

AGP starts MediPharm Labs at buy; PT $2 (Canadian)

Alliance Global Partners initiated coverage of MediPharm Labs (TSX:LABS) with a “buy” rating and price target of $2 (Canadian). The stock was quote at 82 cents around midday on Nov. 2. “We see MediPharm in a position to...

November 2, 2020

Markets

Cowen starts Aziyo Biologics at OP; PT $20

Cowen initiated coverage of Aziyo Biologics (NASDAQ:AZYO) with an “outperform” rating an $20 price target. The stock closed at $10.98 on Oct. 30. Aziyo is a regenerative medicine company that has a three-pronged...

November 2, 2020

Markets

AGP ups T2 Biosystems PT to $1.65 from $1.10

Alliance Global Partners raised its price target for T2 Biosystems (NASDAQ:TTOO) to $1.65 from $1.10 after hosting an investor webcast with the company’s CEO and CFO. The stock closed at $1.34 on Oct. 30. “Our...

November 2, 2020

Markets

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

October 30, 2020

Markets

Chardan starts DURECT at buy; PT $7

Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

October 30, 2020

Markets

William Blair starts Aspira Women’s Health at OP

William Blair launched coverage of Aspira Women’s Health (NASDAQ:AWH) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. The company’s current product line, the OVA family, is used for presurgical pelvic...

October 30, 2020

Markets

William Blair starts DermTech at OP

William Blair initiated coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating. The stock closed at $11.75 on Oct. 29. Analyst Brian Weinstein writes that DermTech is focused on driving adoption of its non...

October 30, 2020

Markets

Chardan starts Axcella Health at buy; PT $16

Chardan Capital Markets initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $16 price target. The stock closed at $4.45 on Oct. 26 “We expect that Axcella’s pipeline of endogenous metabolic...

October 27, 2020

Markets

WB starts Silence Therapeutics at OP; fair value estimate $31

William Blair launched coverage of Silence Therapeutics (NASDAQ:SLN) with an “outperform” rating and fair value estimate of $31. The stock closed at $15.50 on Oct. 26. Silence Therapeutics is developing a GalNAc...

October 27, 2020

Markets

HCW cuts Catabasis Pharma to neutral; removes PT

H.C. Wainwright downgraded Catabasis Pharmaceuticals (NASDAQ:CATB) to “neutral” from “buy” and removed its price target after the company announced that the Phase 3 PolarisDMD trial testing edasalonexent in 131 patients...

October 27, 2020

Markets

Ladenburg starts Immunome at buy; PT $28

Ladenburg Thalmann initiated coverage of Immunome (NASDAQ:IMNM) with a “buy” rating and price target of $28. The stock closed at $11.74 on Oct. 23. Immunome is using its Immunome Discovery Engine (IDE) platform to...

October 26, 2020

Markets

SVB Leerink starts Athenex at OP; PT $22

SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...

October 26, 2020

Markets

Mackie starts CB2 Insights at speculative buy; PT $1.10 (Canadian)

Mackie Research Capital initiated coverage of CB2 Insights (CSE:CBII) with a “speculative buy” rating and price target of $1.10. The stock closed at 59 cents on Oct. 23. CB2 Insights is a health care services and...

October 26, 2020

Markets

Brookline starts electroCore at buy; PT $5

Brookline Capital Markets launched coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and price target of $5. The stock closed at $1.57 on Oct. 22. electroCore is a bioelectronic medicine company whose lead...

October 23, 2020

Markets

BTIG starts Progenity at buy; PT $12

BTIG initiated coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $12. The stock closed at $7.80 on Oct. 22. Progenity is one of the top providers of non-invasive prenatal testing (NIPT) and...

October 23, 2020

Markets

Brookline starts CTI Biopharma at buy; PT $7

Brookline Capital Markets initiated coverage of CTI BioPharma (NASDAQ:CTIC) with a “buy” rating and $7 price target. The stock closed at $3.34 on Oct. 22. CTI is focused on novel targeted therapies for hematologic...

October 23, 2020

Markets

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

October 22, 2020

Markets

Stifel starts Orthofix Medical at buy; PT $39

Stifel launched coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and price target of $39. The stock closed at $34.05 on Oct. 19. Orthofix is focused on providing medical devices, operating through the...

October 19, 2020

Markets

Stifel starts Alphatec at buy; PT $13

Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...

October 19, 2020

Subscribe